In vivo evaluation of pH-sensitive polymer-based immunoliposomes targeting the CD33 antigen

Molecular Pharmaceutics

Volumn 7, Issue 4, 2010, Pages 1099-1107

  Simard, Pierre ^a   Leroux, Jean Christophe ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b ETH ZURICH   (Switzerland)

Author keywords

acute myeloid leukemia; ara C; Immunoliposomes; N isopropylacrylamide; pH sensitive copolymers; pharmacokinetics

Indexed keywords

CD33 ANTIGEN; COPOLYMER; CYTARABINE; IMMUNOLIPOSOME; METHACRYLIC ACID; MONOCLONAL ANTIBODY; POLY(N ISOPROPYLACRYLAMIDE); ACRYLAMIDE DERIVATIVE; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN; LIPOSOME; N ISOPROPYLACRYLAMIDE; N-ISOPROPYLACRYLAMIDE; POLYMER;

ANIMAL CELL; ARTICLE; CELL STRAIN HL 60; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG FORMULATION; ENCAPSULATION; FEMALE; IN VIVO STUDY; LEUKEMIA CELL; MOUSE; MYELOID LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOLOGY; MOUSE MUTANT; PH;

ACRYLAMIDES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HL-60 CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; LEUKEMIA, MYELOID, ACUTE; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, SCID; POLYMERS;

EID: 77955247994     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp900261m     Document Type: Article

References (53)

1. McCulloch, E. A. Stem cells in normal and leukemic hemopoiesis Blood 1983, 62, 1-13
2. Bishop, J. F. The treatment of adult acute myeloid leukemia Semin. Oncol. 1997, 24, 57-69
3. Plagemann, P. G.; Marz, R.; Wohlhueter, R. M. Transport and metabolism of deoxycytidine and 1-beta-D-arabinofuranosylcytosine into cultured Novikoff rat hepatoma cells, relationship to phosphorylation, and regulation of triphosphate synthesis Cancer Res. 1978, 38, 978-89
4. Powis, G., Anticancer drugs: antimetabolite metabolism and natural anticancer agents. In International encyclopedia of pharmacology and therapeutics; Powis, G., Ed.; Pergamon Press: Oxford, 1994; pp 71 -' 94.
5. Kufe, D. W.; Munroe, D.; Herrick, D.; Egan, E.; Spriggs, D. Effects of 1-beta-D-arabinofuranosylcytosine incorporation on eukaryotic DNA template function Mol. Pharmacol. 1984, 26, 128-34
6. Muus, P.; Haanen, C.; Raijmakers, R.; de Witte, T.; Salden, M.; Wessels, J. Influence of dose and duration of exposure on the cytotoxic effect of cytarabine toward human hematopoietic clonogenic cells Semin. Oncol. 1987, 14, 238-44
7. Plunkett, W.; Liliemark, J. O.; Estey, E.; Keating, M. J. Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C Semin. Oncol. 1987, 14, 159-66
8. Estey, E. H. Therapeutic options for acute myelogenous leukemia Cancer 2001, 92, 1059-73
9. Galmarini, C. M.; Thomas, X.; Calvo, F.; Rousselot, P.; El Jafaari, A.; Cros, E.; Dumontet, C. Potential mechanisms of resistance to cytarabine in AML patients Leuk. Res. 2002, 26, 621-9
10. Leith, C. P.; Chen, I. M.; Kopecky, K. J.; Appelbaum, F. R.; Head, D. R.; Godwin, J. E.; Weick, J. K.; Willman, C. L. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-'/efflux+ and MDR1+/efflux-' cases Blood 1995, 86, 2329-42
11. Allen, T. M.; Mehra, T.; Hansen, C.; Chin, Y. C. Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine Cancer Res. 1992, 52, 2431-9
12. Hamada, A.; Kawaguchi, T.; Nakano, M. Clinical pharmacokinetics of cytarabine formulations Clin. Pharmacokinet. 2002, 41, 705-18
13. Brown, P. M.; Silvius, J. R. Mechanisms of delivery of liposome-encapsulated cytosine arabinoside to CV-1 cells in vitro. Fluorescence-microscopic and cytotoxicity studies Biochim. Biophys. Acta 1990, 1023, 341-51
14. Ho, R. J.; Rouse, B. T.; Huang, L. Target-sensitive immunoliposomes as an efficient drug carrier for antiviral activity J. Biol. Chem. 1987, 262, 13973-8
15. Connor, J.; Huang, L. pH-sensitive immunoliposomes as an efficient and target-specific carrier for antitumor drugs Cancer Res. 1986, 46, 3431-35
16. Simard, P.; Leroux, J. C. pH-sensitive immunoliposomes specific to the CD33 cell surface antigen of leuk emic cells Int. J. Pharm. 2009, 381, 86-96
17. Scheinberg, D. A.; Tanimoto, M.; McKenzie, S.; Strife, A.; Old, L. J.; Clarkson, B. D. Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia Leukemia 1989, 3, 440-5
18. Griffin, J. D.; Linch, D.; Sabbath, K.; Larcom, P.; Schlossman, S. F. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells Leuk. Res. 1984, 8, 521-34
19. Larson, R. A.; Sievers, E. L.; Stadtmauer, E. A.; Lowenberg, B.; Estey, E. H.; Dombret, H.; Theobald, M.; Voliotis, D.; Bennett, J. M.; Richie, M.; Leopold, L. H.; Berger, M. S.; Sherman, M. L.; Loken, M. R.; van Dongen, J. J.; Bernstein, I. D.; Appelbaum, F. R. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence Cancer 2005, 104, 1442-52
20. Huang, A.; Kennel, S. J.; Huang, L. Interactions of immunoliposomes with target cells J. Biol. Chem. 1983, 258, 14034-40
21. Rustum, Y. M.; Dave, C.; Mayhew, E.; Papahadjopoulos, D. Role of liposome type and route of administration in the antitumor activity of liposome-entrapped 1-beta-D-arabinofuranosylcytosine against mouse L1210 leukemia Cancer Res. 1979, 39, 1390-95
22. Roux, E.; Stomp, R.; Giasson, S.; Pézolet, M.; Moreau, P.; Leroux, J.-C. Steric stabilization of liposomes by pH-responsive N -isopropylacrylamide copolymer J. Pharm. Sci. 2002, 91, 1795-802
23. Bertrand, N.; Fleischer, J. G.; Wasan, K. M.; Leroux, J.-C. Pharmacokinetics and biodistribution of N-isopropylacrylamide copolymers for the design of pH-sensitive liposomes Biomaterials 2009, 30, 2598-605
24. Francis, M. F.; Dhara, G.; Winnik, F. M.; Leroux, J.-C. In vitro evaluation of pH-sensitive polymer/niosome complexes Biomacromolecules 2001, 2, 741-9
25. Roux, E.; Francis, M.; Winnik, F. M.; Leroux, J.-C. Polymer-based pH-sensitive carriers as a means to improve the cytoplasmic delivery of drugs Int. J. Pharm. 2002, 242, 25-36
26. Leroux, J.-C.; Roux, E.; Le Garrec, D.; Hong, K.; Drummond, D. C. N-Isopropylacrylamide copolymers for the preparation of pH-sensitive liposomes and polymeric micelles J. Controlled Release 2001, 72, 71-84
27. Bartlett, G. R. Phosphorus assay in column chromatography J. Biol. Chem. 1959, 234, 466-8
28. Fonseca, C.; Moreira, J. N.; Ciudad, C. J.; Pedroso de Lima, M. C.; Simoes, S. Targeting of sterically stabilised pH-sensitive liposomes to human T-leukaemia cells Eur. J. Pharm. Biopharm. 2005, 59, 359-66
29. Gubernator, J.; Drulis-Kawa, Z.; Kozubek, A. A simply and sensitive fluorometric method for determination of gentamicin in liposomal suspensions Int. J. Pharm. 2006, 327, 104-9
30. Esposito, E.; Pastesini, C.; Cortesi, R.; Gambari, R.; Menegatti, E.; Nastruzzi, C. Controlled release of 1-b-D-arabinofuranosylcytosine (ara-C) from hydrophilic gelatin microspheres: in vitro studies Int. J. Pharm. 1995, 117, 151-8
31. Drummond, D. C.; Zignani, M.; Leroux, J.-C. Current status of pH-sensitive liposomes in drug delivery Prog. Lipid Res. 2000, 39, 409-60
32. Roux, E.; Passirani, C.; Scheffold, S.; Benoit, J. P.; Leroux, J.-C. Serum-stable and long-circulating, PEGylated, pH-sensitive liposomes J. Controlled Release 2004, 94, 447-51
33. Mariani, M.; Camagna, M.; Tarditi, L.; Seccamani, E. A new enzymatic method to obtain high-yield F(ab)2 suitable for clinical use from mouse IgGl Mol. Immunol. 1991, 28, 69-77
34. Sapra, P.; Allen, T. M. Ligand-targeted liposomal anticancer drugs Prog. Lipid Res. 2003, 42, 439-62
35. Huwyler, J.; Wu, D.; Pardridge, W. M. Brain drug delivery of small molecules using immunoliposomes Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 14164-9
36. Dufresne, I.; Desormeaux, A.; Bestman-Smith, J.; Gourde, P.; Tremblay, M. J.; Bergeron, M. G. Targeting lymph nodes with liposomes bearing anti-HLA-DR Fab' fragments Biochim. Biophys. Acta 1999, 1421, 284-94
37. Roux, E.; Lafleur, M.; Lataste, E.; Moreau, P.; Leroux, J.-C. On the characterization of pH-sensitive liposome/polymer complexes Biomacromolecules 2003, 4, 240-8
38. Maruyama, K.; Takizawa, T.; Yuda, T.; Kennel, S. J.; Huang, L.; Iwatsuru, M. Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies Biochim. Biophys. Acta 1995, 1234, 74-80
39. Drummond, D. C.; Meyer, O.; Hong, K.; Kirpotin, D.; Papahadjopoulos, D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors Pharmacol. Rev. 1999, 51, 691-743
40. Sapra, P.; Moase, E. H.; Ma, J.; Allen, T. M. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments Clin. Cancer Res. 2004, 10, 1100-11
41. Maruyama, K.; Takahashi, N.; Tagawa, T.; Nagaike, K.; Iwatsuru, M. Immunoliposomes bearing polyethyleneglycol-coupled Fab' fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo FEBS Lett. 1997, 413, 177-80
42. Cheng, W. W.; Allen, T. M. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv J. Controlled Release 2008, 126, 50-8
43. Aragnol, D.; Leserman, L. D. Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 2699-703
44. Ansell, S. M.; Tardi, P. G.; Buchkowsky, S. S. 3-(2-Pyridyldithio) propionic acid hydrazide as a cross-linker in the formation of liposome-antibody conjugates Bioconjugate Chem. 1996, 7, 490-6
45. Harasym, T. O.; Bally, M. B.; Tardi, P. Clearance properties of liposomes involving conjugated proteins for targeting Adv. Drug Delivery Rev. 1998, 32, 99-118
46. Allen, T. M.; Brandeis, E.; Hansen, C. B.; Kao, G. Y.; Zalipsky, S. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells Biochim. Biophys. Acta 1995, 1237, 99-108
47. Juliano, R. L.; Stamp, D. Pharmacokinetics of liposome-encapsulated anti-tumor drugs. Studies with vinblastine, actinomycin D, cytosine arabinoside, and daunomycin Biochem. Pharmacol. 1978, 27, 21-7
48. Williams, S. S.; Alosco, T. R.; Mayhew, E.; Lasic, D. D.; Martin, F. J.; Bankert, R. B. Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes Cancer Res. 1993, 53, 3964-7
49. Xu, Y.; Scheinberg, D. A. Elimination of human leukemia by monoclonal antibodies in an athymic nude mouse leukemia model Clin. Cancer Res. 1995, 1, 1179-87
50. Terpstra, W.; Prins, A.; Visser, T.; Wognum, B.; Wagemaker, G.; Lowenberg, B.; Wielenga, J. Conditions for engraftment of human acute myeloid leukemia (AML) in SCID mice Leukemia 1995, 9, 1573-7
51. Custer, R. P.; Bosma, G. C.; Bosma, M. J. Severe combined immunodeficiency (SCID) in the mouse. Pathology, reconstitution, neoplasms Am. J. Pathol. 1985, 120, 464-77
52. Skipper, H. E.; Schabel, F. M.; Wilcox, W. S. Experimental evaluation of potential anticancer agents. XXI. Scheduling of arabinosylcytosine to take advantage of its S-phase specificity against leukemia cells Cancer Chemother. Rep. 1967, 51, 125-65
53. Skipper, H. E.; Schabel, F. M., Jr.; Mellett, L. B.; Montgomery, J. A.; Wilkoff, L. J.; Lloyd, H. H.; Brockman, R. W. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules Cancer Chemother. Rep. 1970, 54, 431-50